Edward M. Kaye

2014 - Sarepta Therapeutics

In 2014, Edward M. Kaye earned a total compensation of $1.7M as President and Chief Executive Officer at Sarepta Therapeutics, a 36% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$131,676
Option Awards$1,155,231
Salary$399,017
Other$17,797
Total$1,703,721

Kaye received $1.2M in option awards, accounting for 68% of the total pay in 2014.

Kaye also received $131.7K in non-equity incentive plan, $399K in salary and $17.8K in other compensation.

Rankings

In 2014, Edward M. Kaye's compensation ranked 5,212th out of 13,032 executives tracked by ExecPay. In other words, Kaye earned more than 60.0% of executives.

ClassificationRankingPercentile
All
5,212
out of 13,032
60th
Division
Manufacturing
1,863
out of 4,966
63rd
Major group
Chemicals And Allied Products
623
out of 1,686
63rd
Industry group
Drugs
475
out of 1,365
65th
Industry
Pharmaceutical Preparations
376
out of 1,043
64th
Source: SEC filing on April 27, 2017.

Kaye's colleagues

We found five more compensation records of executives who worked with Edward M. Kaye at Sarepta Therapeutics in 2014.

2014

Christopher Garabedian

Sarepta Therapeutics

Chief Executive Officer

2014

Arthur Krieg

Sarepta Therapeutics

Chief Scientific Officer

2014

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

2014

David Howton

Sarepta Therapeutics

General Counsel

2014

Jayant Aphale

Sarepta Therapeutics

Senior Vice President, Technical Operations

News

In-depth

You may also like